NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantum BioPharma's Market Manipulation Allegations and CTV W5 Coverage
TL;DR
Quantum BioPharma's $700 million lawsuit against CIBC and RBC could expose market manipulation, potentially creating a legal advantage for investors monitoring stock spoofing allegations.
Quantum BioPharma alleges stock spoofing through millions of illegal orders from bank platforms, detailed in CTV News' W5 series and supported by Canadian exchange data.
Quantum BioPharma's lawsuit aims to protect market integrity, supporting their development of Lucid-MS to potentially treat multiple sclerosis and improve patient outcomes.
CTV News' W5 aired Part 2 investigating Quantum BioPharma's claims of widespread market manipulation tied to their $700 million lawsuit against major Canadian banks.
Found this article helpful?
Share it with your network and spread the knowledge!
The article covers Quantum BioPharma Ltd.'s allegations of stock spoofing and market manipulation, which are being featured in CTV News' W5 investigative series Part 2, and the company's $700 million lawsuit against CIBC and RBC.
CTV's investigative program W5 is airing a three-part series examining Quantum BioPharma's allegations of stock spoofing tied to their $700 million lawsuit against CIBC and RBC, with Part 2 highlighting the company's claims of widespread market manipulation.
Quantum BioPharma Ltd. (CEO Zeeshan Saeed and Co-Executive Chair Anthony Durkacz) is making allegations against CIBC and RBC, claiming millions of purportedly illegal orders originated from bank platforms according to Canadian exchange data cited in their lawsuit.
Quantum BioPharma's lead compound is Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation (the underlying mechanism of multiple sclerosis) in preclinical models, developed through their subsidiary Lucid Psycheceuticals Inc.
According to the company, the alleged market manipulation has impacted Quantum BioPharma's efforts to advance Lucid-MS, their potential multiple sclerosis treatment.
Quantum BioPharma has filed a $700 million lawsuit against CIBC and RBC related to the alleged stock spoofing and market manipulation.
Quantum BioPharma invented unbuzzd™ (with an OTC version spun out to Unbuzzd Wellness Inc.), retains 20.11% ownership of Unbuzzd Wellness Inc. as of March 31, 2025, receives royalty payments from unbuzzd™ sales, and maintains strategic investments through subsidiary FSD Strategic Investments Inc.
The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
InvestorWire is a specialized communications platform that syndicated this press release as part of paid advertising on behalf of Quantum BioPharma Ltd., and is one of 70+ brands within IBN's Dynamic Brand Portfolio.
Curated from InvestorBrandNetwork (IBN)
